Last reviewed · How we verify

Haemocomplettan® P — Competitive Intelligence Brief

Haemocomplettan® P (Haemocomplettan® P) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prothrombin complex concentrate (PCC). Area: Hematology.

marketed Prothrombin complex concentrate (PCC) Clotting factors II, VII, IX, X Hematology Biologic Live · refreshed every 30 min

Target snapshot

Haemocomplettan® P (Haemocomplettan® P) — CSL Behring. Haemocomplettan® P is a prothrombin complex concentrate (PCC) that replaces deficient vitamin K-dependent clotting factors to restore coagulation capacity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Haemocomplettan® P TARGET Haemocomplettan® P CSL Behring marketed Prothrombin complex concentrate (PCC) Clotting factors II, VII, IX, X
Nadroparin Calcium and Warfarin Nadroparin Calcium and Warfarin Shanghai Zhongshan Hospital marketed Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist) Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
nadroparin calcium-warfarin sequential anticoagulation nadroparin calcium-warfarin sequential anticoagulation Qilu Hospital of Shandong University marketed Anticoagulant combination (LMWH + vitamin K antagonist) Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Prothrombin Complex Concentrate, Human Prothrombin Complex Concentrate, Human SHI Jia marketed Coagulation factor concentrate Clotting factors II, VII, IX, X (vitamin K-dependent factors)
Enoxaparin followed by VKA Enoxaparin followed by VKA Bayer phase 3 Anticoagulant (low-molecular-weight heparin bridged to vitamin K antagonist) Factor Xa, Factor IIa (enoxaparin); Vitamin K-dependent clotting factors II, VII, IX, X (VKA)
Factor Concentrate (Bebulin) Factor Concentrate (Bebulin) The University of Texas Health Science Center, Houston marketed Prothrombin complex concentrate (PCC) Coagulation factors II, VII, IX, X
Beriplex® P/N (Kcentra) Beriplex® P/N (Kcentra) CSL Behring phase 3 Prothrombin complex concentrate (PCC) Vitamin K-dependent clotting factors (Factors II, VII, IX, X)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prothrombin complex concentrate (PCC) class)

  1. CSL Behring · 2 drugs in this class
  2. The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Haemocomplettan® P — Competitive Intelligence Brief. https://druglandscape.com/ci/haemocomplettan-p. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: